RhumbLine Advisers’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $906K | Buy |
96,280
+9,548
| +11% | +$89.8K | ﹤0.01% | 2296 |
|
|
2025
Q1 | $470K | Sell |
86,732
-2,828
| -3% | -$15.3K | ﹤0.01% | 2616 |
|
|
2024
Q4 | $667K | Buy |
89,560
+12,443
| +16% | +$92.7K | ﹤0.01% | 2481 |
|
|
2024
Q3 | $616K | Buy |
77,117
+284
| +0.4% | +$2.27K | ﹤0.01% | 2559 |
|
|
2024
Q2 | $668K | Buy |
76,833
+18,897
| +33% | +$164K | ﹤0.01% | 2468 |
|
|
2024
Q1 | $1.2M | Buy |
57,936
+11,796
| +26% | +$244K | ﹤0.01% | 2150 |
|
|
2023
Q4 | $1.07M | Buy |
46,140
+4,388
| +11% | +$101K | ﹤0.01% | 2214 |
|
|
2023
Q3 | $334K | Buy |
41,752
+1,328
| +3% | +$10.6K | ﹤0.01% | 2869 |
|
|
2023
Q2 | $352K | Buy |
40,424
+1,208
| +3% | +$10.5K | ﹤0.01% | 2908 |
|
|
2023
Q1 | $115K | Buy |
39,216
+1,481
| +4% | +$4.34K | ﹤0.01% | 2837 |
|
|
2022
Q4 | $132K | Buy |
37,735
+265
| +0.7% | +$927 | ﹤0.01% | 2865 |
|
|
2022
Q3 | $296K | Buy |
37,470
+2,143
| +6% | +$16.9K | ﹤0.01% | 2730 |
|
|
2022
Q2 | $278K | Buy |
35,327
+5,864
| +20% | +$46.1K | ﹤0.01% | 2796 |
|
|
2022
Q1 | $358K | Buy |
29,463
+7,438
| +34% | +$90.4K | ﹤0.01% | 2578 |
|
|
2021
Q4 | $270K | Buy |
22,025
+11
| +0% | +$135 | ﹤0.01% | 2741 |
|
|
2021
Q3 | $229K | Buy |
22,014
+1,365
| +7% | +$14.2K | ﹤0.01% | 2859 |
|
|
2021
Q2 | $186K | Buy |
+20,649
| New | +$186K | ﹤0.01% | 2929 |
|
|
2020
Q2 | – | Sell |
-5,270
| Closed | -$54K | – | 3075 |
|
|
2020
Q1 | $54K | Buy |
5,270
+321
| +6% | +$3.29K | ﹤0.01% | 2854 |
|
|
2019
Q4 | $77K | Sell |
4,949
-130
| -3% | -$2.02K | ﹤0.01% | 2895 |
|
|
2019
Q3 | $92K | Buy |
5,079
+241
| +5% | +$4.37K | ﹤0.01% | 2898 |
|
|
2019
Q2 | $79K | Buy |
+4,838
| New | +$79K | ﹤0.01% | 2941 |
|